Background: Computed tomography (CT)-assessed sarcopenia indexes have been reported to predict postoperative morbidity and mortality; however conclusions drawn from different indexes and studies remain controversial. Aim: The purpose of this meta-analysis was to evaluate various CT-assessed sarcopenia indexes as predictors of risk for major complications in patients undergoing hepatopancreatobiliary surgery for malignancy. Methods: Medline/PubMed, Web of Science, and Embase databases were systematically searched to identify relevant studies published before June 2018. PRISMA guidelines for systematic reviews were followed. The pooled risk ratio (RR) for major postoperative complications (Clavien-Dindo ≥III) was estimated in patients with sarcopenia versus patients without sarcopenia. Data extracted were meta-analyzed using Review Manager (version 5.3). Results: Twenty-eight studies comprising 6,656 patients were included in this study. CT-assessed sarcopenia indexes, such as skeletal muscle index (SMI, RR 1.36; 95% CI 1.14–1.63; p = 0.0008; I2 = 24%), psoas muscle index (PMI, RR 1.35; 95% CI 1.15–1.58; p = 0.0002; I2 = 0%), muscle attenuation (MA, RR 1.40; 95% CI 1.14–1.73; p = 0.002; I2 = 4%), and intramuscular adipose tissue content (IMAC, RR 1.63; 95% CI 1.28–2.09; p < 0.0001; I2 = 0%) were all predictors of postoperative major complications, although moderate heterogeneity existed and cutoffs for these indexes to define sarcopenia varied. Conclusions: All commonly used CT-assessed sarcopenia indexes, such as SMI, PMI, MA, and IMAC can predict the risk of major postoperative complications; however, a consensus on the cutoffs for these indexes to define sarcopenia is still lacking.

Keywords:
Sarcopenia, Computed tomography, Major complications , Surgery, Hepatopancreatobiliary
1.
Ljungqvist O, Scott M, Fearon KC: Enhanced recovery after surgery: a review. JAMA Surg 2017; 152: 292–298.
2.
Green D: Role of Multimodal Monitoring (MMM) in the Perioperative Period: Improving Outcomes in High Risk Surgical Patients [M]/Perioperative Medicine-Current Controversies. Cham, Springer, 2016, pp 271–300.
3.
Kehlet H, Jørgensen CC: Advancing surgical outcomes research and quality improvement within an enhanced recovery program framework. Ann Surg 2016; 264: 237–238.
4.
Blake P, Patel N, Brown C, Blackshaw G, Powell AG, Wheat J, Beamish A, Lewis WG: Prognostic significance of body composition determined by bioelectrical impedance analysis (BIA) in upper gastrointestinal cancer surgery. Gastroenterology 2017; 152: S1269.
5.
Nakashima Y, Saeki H, Nakanishi R, Sugiyama M, Kurashige J, Oki E, Maehara Y: Assessment of sarcopenia as a predictor of poor outcomes after esophagectomy in elderly patients with esophageal cancer. Ann Surg 2017; 267: 1100–1104.
6.
Hirasawa Y, Nakashima J, Yunaiyama D, Sugihara T, Gondo T, Nakagami Y, Horiguchi Y, Ohno Y, Namiki K, Ohori M, Tokuuye K, Tachibana M: Sarcopenia as a novel preoperative prognostic predictor for survival in patients with bladder cancer undergoing radical cystectomy. Ann Surg Oncol 2016; 23(suppl 5): 1048–1054.
7.
Gillen J, Mills KA, Dvorak J, Zheng B, Thai T, Salani R, Cosgrove CM, Davidson B, Thaker PH, Moore KN: Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab. Gynecol Oncol 2017; 147: 198–199.
8.
Rosenberg IH: Summary comments: epidemiological and methodological problems in determining nutritional status of older persons. Am J Clin Nutr 1989; 50: 1231–1233.
9.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People: Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing 2010; 39: 412–423.
10.
Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, Compher C, Correia I, Higashiguchi T, Holst M, Jensen GL, Malone A, Muscaritoli M, Nyulasi I, Pirlich M, Rothenberg E, Schindler K, Schneider SM, de van der Schueren MA, Sieber C, Valentini L, Yu JC, Van Gossum A, Singer P: ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr 2017; 36: 49–64.
11.
Kobayashi A, Kaido T, Hamaguchi Y, Okumura S, Shirai H, Kamo N, Yagi S, Taura K, Okajima H, Uemoto S: Impact of sarcopenic obesity on outcomes in patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg 2017, DOI: 10.1097/SLA.0000000000002555.
12.
Amini N, Spolverato G, Gupta R, Margonis GA, Kim Y, Wagner D, Rezaee N, Weiss MJ, Wolfgang CL, Makary MM, Kamel IR, Pawlik TM: Impact total psoas volume on short- and long-term outcomes in patients undergoing curative resection for pancreatic adenocarcinoma: a new tool to assess sarcopenia. J Gastrointest Surg 2015; 19: 1593–1602.
13.
Okumura S, Kaido T, Hamaguchi Y, Kobayashi A, Shirai H, Fujimoto Y, Iida T, Yagi S, Taura K, Hatano E, Okajima H, Uemoto S: Impact of skeletal muscle mass, muscle quality, and visceral adiposity on outcomes following resection of intrahepatic cholangiocarcinoma. Ann Surg Oncol 2017; 24: 1037–1045.
14.
Onesti JK, Wright GP, Kenning SE, Tierney MT, Davis AT, Doherty MG, Chung MH: Sarcopenia and survival in patients undergoing pancreatic resection. Pancreatology 2016; 16: 284–289.
15.
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M: The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187–196.
16.
Wells GA, Shea B, O’Connell D, et al: The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analysis. Ottawa, The Ottawa Health Research Institute, 2011.
17.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
18.
Brockwell SE, Gordon IR: A comparison of statistical methods for meta-analysis. Stat Med 2001; 20: 825–840.
19.
Coelen RJ, Wiggers JK, Nio CY, Besselink MG, Busch OR, Gouma DJ, van Gulik TM: Preoperative computed tomography assessment of skeletal muscle mass is valuable in predicting outcomes following hepatectomy for perihilar cholangiocarcinoma. HPB (Oxford) 2015; 17: 520–528.
20.
Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Fujimoto Y, Ogawa K, Mori A, Hammad A, Hatano E, Uemoto S: Muscle steatosis is an independent predictor of postoperative complications in patients with hepatocellular carcinoma. World J Surg 2016; 40: 1959–1968.
21.
Higashi T, Hayashi H, Taki K, Sakamoto K, Kuroki H, Nitta H, Hashimoto D, Chikamoto A, Beppu T, Baba H: Sarcopenia, but not visceral fat amount, is a risk factor of postoperative complications after major hepatectomy. Int J Clin Oncol 2016; 21: 310–319.
22.
Coelen RJ, van Gulik TM: Preoperative sarcopenia negatively impacts postoperative outcomes following major hepatectomy with extrahepatic bile duct resection. World J Surg 2015; 39: 2368–2369.
23.
Takagi K, Yagi T, Yoshida R, Shinoura S, Umeda Y, Nobuoka D, Kuise T, Watanabe N, Fujiwara T: Sarcopenia and American society of anesthesiologists physical status in the assessment of outcomes of hepatocellular carcinoma patients undergoing hepatectomy. Acta Med Okayama 2016; 70: 363–370.
24.
Voron T, Tselikas L, Pietrasz D, Pigneur F, Laurent A, Compagnon P, Salloum C, Luciani A, Azoulay D: Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma. Ann Surg 2015; 261: 1173–1183.
25.
Yabusaki N, Fujii T, Yamada S, Suzuki K, Sugimoto H, Kanda M, Nakayama G, Koike M, Fujiwara M, Kodera Y: Adverse impact of low skeletal muscle index on the prognosis of hepatocellular carcinoma after hepatic resection. Int J Surg 2016; 30: 136–142.
26.
Zhou G, Bao H, Zeng Q, Hu W, Zhang Q: Sarcopenia as a prognostic factor in hepatolithiasis-associated intrahepatic cholangiocarcinoma patients following hepatectomy: a retrospective study. Int J Clin Exp Med 2015; 8: 18245–18254.
27.
Kobayashi A, Kaido T, Hamaguchi Y, Okumura S, Shirai H, Kamo N, Yagi S, Taura K, Okajima H, Uemoto S: Impact of visceral adiposity as well as sarcopenic factors on outcomes in patients undergoing liver resection for colorectal liver metastases. World J Surg 2018; 42: 1180–1191.
28.
Lodewick TM, van Nijnatten TJ, van Dam RM, van Mierlo K, Dello SA, Neumann UP, Olde Damink SW, Dejong CH: Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases? HPB (Oxford) 2015; 17: 438–446.
29.
Peng PD, Van Vledder MG, Tsai S, de Jong MC, Makary M, Ng J, Edil BH, Wolfgang CL, Schulick RD, Choti MA, Kamel I, Pawlik TM: Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford) 2011; 13: 439–446.
30.
Chakedis J, Spolverato G, Beal EW, Woelfel I, Bagante F, Merath K, Sun SH, Chafitz A, Galo J, Dillhoff M, Cloyd J, Pawlik TM: Pre-operative sarcopenia identifies patients at risk for poor survival after resection of biliary tract cancers. J Gastrointest Surg 2018: 1697–1708.
31.
Okumura S, Kaido T, Hamaguchi Y, Fujimoto Y, Kobayashi A, Iida T, Yagi S, Taura K, Hatano E, Uemoto S: Impact of the preoperative quantity and quality of skeletal muscle on outcomes after resection of extrahepatic biliary malignancies. Surgery 2016; 159: 821–833.
32.
Choi MH, Yoon SB, Lee K, Song M, Lee IS, Lee MA, Hong TH, Choi MG: Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. J Cachexia Sarcopenia Muscle 2018; 9: 326–334.
33.
Okumura S, Kaido T, Hamaguchi Y, Fujimoto Y, Masui T, Mizumoto M, Hammad A, Mori A, Takaori K, Uemoto S: Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Surgery 2015; 157: 1088–1098.
34.
Okumura S, Kaido T, Hamaguchi Y, Kobayashi A, Shirai H, Yao S, Yagi S, Kamo N, Hatano E, Okajima H, Takaori K, Uemoto S: Visceral adiposity and sarcopenic visceral obesity are associated with poor prognosis after resection of pancreatic cancer. Ann Surg Oncol 2017; 24: 3732–3740.
35.
Wagner D, Marsoner K, Tomberger A, Haybaeck J, Haas J, Werkgartner G, Cerwenka H, Bacher H, Mischinger HJ, Kornprat P: Low skeletal muscle mass outperforms the Charlson comorbidity index in risk prediction in patients undergoing pancreatic resections. Eur J Surg Oncol 2018; 44: 658–663.
36.
Sui K, Okabayshi T, Iwata J, Morita S, Sumiyoshi T, Iiyama T, Shimada Y: Correlation between the skeletal muscle index and surgical outcomes of pancreaticoduodenectomy. Surg Today 2018; 48: 545–551.
37.
Van Rijssen LB, van Huijgevoort NC, Coelen RJ, Tol JA, Haverkort EB, Nio CY, Busch OR, Besselink MG: Skeletal muscle quality is associated with worse survival after pancreatoduodenectomy for periampullary, nonpancreatic cancer. Ann Surg Oncol 2017; 24: 272–280.
38.
Stretch C, Aubin JM, Mickiewicz B, Leugner D, Al-Manasra T, Tobola E, Salazar S, Sutherland FR, Ball CG, Dixon E, Vogel HJ, Damaraju S, Baracos VE, Bathe OF: Sarcopenia and myosteatosis are accompanied by distinct biological profiles in patients with pancreatic and periampullary adenocarcinomas. PLoS One 2018; 13:e0196235.
39.
Nishida Y, Kato Y, Kudo M, Aizawa H, Okubo S, Takahashi D, Nakayama Y, Kitaguchi K, Gotohda N, Takahashi S, Konishi M: Preoperative sarcopenia strongly influences the risk of postoperative pancreatic fistula formation after pancreaticoduodenectomy. J Gastrointest Surg 2016; 20: 1586–1594.
40.
Takagi K, Yoshida R, Yagi T, Umeda Y, Nobuoka D, Kuise T, Fujiwara T: Radiographic sarcopenia predicts postoperative infectious complications in patients undergoing pancreaticoduodenectomy. BMC Surg 2017; 17: 64.
41.
van Dijk DP, Bakens MJ, Coolsen MM, Rensen SS, van Dam RM, Bours MJ, Weijenberg MP, Dejong CH, Olde Damink SW: Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer. J Cachexia Sarcopenia Muscle 2017; 8: 317–326.
42.
Takagi K, Yagi T, Yoshida R, Umeda Y, Nobuoka D, Kuise T, Fujiwara T: Sarcopenia predicts postoperative infection in patients undergoing hepato-biliary-pancreatic surgery. Int J Surg 2017; 6: 12–18.
43.
Hamaguchi Y, Kaido T, Okumura S, Ito T, Fujimoto Y, Ogawa K, Mori A, Hammad A, Hatano E, Uemoto S: Preoperative intramuscular adipose tissue content is a novel prognostic predictor after hepatectomy for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2015; 22: 475–485.
44.
Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Shirai H, Yagi S, Kamo N, Okajima H, Uemoto S: Impact of skeletal muscle mass index, intramuscular adipose tissue content, and visceral to subcutaneous adipose tissue area ratio on early mortality of living donor liver transplantation. Transplantation 2017; 101: 565–574.
45.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE: Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489–495.
46.
Van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN: Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 2012; 99: 550–557.
47.
Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE: Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31: 1539–1547.
48.
Duceppe E, Lauzon JF, Gallinger S, Zhang B, Solomon H, Aybar PS: 956-Predictors of splanchnic vein thrombosis and mortality following hepatobiliary and pancreatic purgery. Gastroenterology 2018; 154:S1296.
49.
Bos S, Bernal W, Porte RJ, Lisman T: Hemostatic complications in hepatobiliary surgery. Semin Thromb Hemost 2017; 43: 732–741.
50.
El Amrani M, Fulbert M, Lenne X, Clément G, Drumez E, Pruvot FR, Truant S: Do complications following pancreatic resections impact hospital costs in France: medico-economic study on 127 patients. J Visc Surg 2018;pii:S1878-7886(18)30055-9.
51.
Van Vugt JLA, Buettner S, Levolger S, Coebergh van den Braak RRJ, Suker M, Gaspersz MP, de Bruin RWF, Verhoef C, van Eijck CHC, Bossche N, Groot Koerkamp B, IJzermans JNM: Low skeletal muscle mass is associated with increased hospital expenditure in patients undergoing cancer surgery of the alimentary tract. PLoS One 2017; 12:e0186547.
52.
Murimwa GZ, Venkat PS, Jin W, Leuthold S, Latifi K, Almhanna K, Pimiento JM, Fontaine JP, Hoffe SE, Frakes JM: Impact of sarcopenia on outcomes of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery. J Gastrointest Oncol 2017; 8: 808–815.
53.
Kim EY, Lee HY, Kim KW, Lee JI, Kim YS, Choi WJ, Kim JH: Preoperative computed tomography-determined sarcopenia and postoperative outcome after surgery for non-small cell lung cancer. Scand J Surg 2018; 107: 244–251.
54.
van Vugt JLA, Alferink LJM, Buettner S, Gaspersz MP, Bot D, Darwish Murad S, Feshtali S, van Ooijen PMA, Polak WG, Porte RJ, van Hoek B, van den Berg AP, Metselaar HJ, IJzermans JNM: A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: a competing risk analysis in a national cohort. J Hepatol 2018; 68: 707–714.
55.
Rutten IJG, Ubachs J, Kruitwagen RFPM, Beets-Tan RGH, Olde Damink SWM, Van Gorp T: Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. J Cachexia Sarcopenia Muscle 2017; 8: 630–638.
56.
Baracos VE: Psoas as a sentinel muscle for sarcopenia: a flawed premise. J Cachexia Sarcopenia Muscle 2017; 8: 527–528.
57.
Womer AL, Brady JT, Kalisz K, Patel ND, Paspulati RM, Reynolds HL, Pawlik TM, Steele SR: Do psoas muscle area and volume correlate with postoperative complications in patients undergoing rectal cancer resection? Am J Surg 2018; 215: 503–506.
58.
Pedersen M, Cromwell J, Nau P: Sarcopenia is a predictor of surgical morbidity in inflammatory bowel disease. Inflamm Bowel Dis 2017; 23: 1867–1872.
59.
Hawkins RB, Mehaffey JH, Charles EJ, Kern JA, Lim DS, Teman NR, Ailawadi G: Psoas muscle size predicts risk-adjusted outcomes after surgical aortic valve replacement. Ann Thorac Surg 2018; 106: 39–45.
60.
Peng P, Hyder O, Firoozmand A, Kneuertz P, Schulick RD, Huang D, Makary M, Hirose K, Edil B, Choti MA, Herman J, Cameron JL, Wolfgang CL, Pawlik TM: Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg 2012; 16: 1478–1486.
61.
Valero V, Amini N, Spolverato G, Weiss MJ, Hirose K, Dagher NN, Wolfgang CL, Cameron AA, Philosophe B, Kamel IR, Pawlik TM: Sarcopenia adversely impacts postoperative complications following resection or transplantation in patients with primary liver tumors. J Gastrointest Surg 2015; 19: 272–281.
62.
Kitajima Y, Hyogo H, Sumida Y, Eguchi Y, Ono N, Kuwashiro T, Tanaka K, Takahashi H, Mizuta T, Ozaki I, Eguchi T, Kimura Y, Fujimoto K, Anzai K; Japan Nonalcoholic Fatty Liver Disease Study Group (JSG-NAFLD): Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle. J Gastroenterol Hepatol 2013; 28: 1507–1514.
63.
Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watadani T, Nakagomi R, Kondo M, Nakatsuka T, Minami T, Sato M, Uchino K, Enooku K, Kondo Y, Asaoka Y, Tanaka Y, Ohtomo K, Shiina S, Koike K: Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 2015; 63: 131–140.
64.
Joglekar S, Asghar A, Mott SL, Johnson BE, Button AM, Clark E, Mezhir JJ: Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. J Surg Oncol 2015; 111: 771–775.
65.
Miller BS, Ignatoski KM, Daignault S, Lindland C, Doherty M, Gauger PG, Hammer GD, Wang SC, Doherty GM; University of Michigan Analytical Morphomics Group: Worsening central sarcopenia and increasing intra-abdominal fat correlate with decreased survival in patients with adrenocortical carcinoma. World J Surg 2012; 36: 1509–1516.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.